Federal Regulation of Interstate Commerce

The Federal Regulation of Interstate Commerce refers to the authority of the federal government to regulate commerce between states. This authority is granted by the Commerce Clause of the U.S. Constitution. The regulation of interstate commerce impacts employee benefits in various ways, including the regulation of employee benefit plans that are established or maintained by employers engaged in interstate commerce.

Key features of the federal regulation of interstate commerce and its impact on employee benefits include:

  • Regulation of Employee Benefit Plans: The federal government has the authority to regulate employee benefit plans that are established or maintained by employers engaged in interstate commerce. This includes pension plans, health plans, and other employee benefit plans.

  • Protection of Employee Rights: Federal laws such as ERISA and the Affordable Care Act provide protections for employee rights with respect to employee benefit plans. These protections include requirements for plan disclosures, fiduciary duties, and non-discrimination.

  • Impact on Employer Compliance: Employers engaged in interstate commerce must comply with federal regulations governing employee benefit plans. Failure to comply can result in penalties and legal liability.

  • State Preemption: The federal regulation of interstate commerce can preempt state laws that regulate employee benefit plans. This means that federal law may take precedence over state law in certain situations.

Overall, the federal regulation of interstate commerce plays a significant role in the regulation of employee benefit plans and the protection of employee rights. Employers engaged in interstate commerce must comply with federal regulations governing employee benefits to avoid penalties and legal liability.

Next Up

Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.
Most U.S. employers now offer paid maternity leave beyond the legal minimum, but coverage varies widely once you look past the basics. According to Mployer Insights' 2026 analysis of more than 50,000 employer benefit plans, 68% of employers provide paid maternity leave on top of short-term disability, typically adding 8 extra weeks, and half now cover 100% of salary during the disability period. Support drops off from there: only 41% of employers offer paid bonding leave for non-birth parents, and advanced family-building benefits remain even less common, with just 28% covering IVF and 11% offering adoption financial assistance. The data suggests that while baseline maternity leave has become standard, more comprehensive family-building support is still the exception rather than the norm.